Tumor-associated antigen presented by major histocompatibility complex class II molecule

Tumor-associated antigens (TAAs) presented by major histocompatibility complex (MHC) class II molecules are tumor-derived peptides displayed on the surface of tumor cells or tumor-associated nonprofessional antigen-presenting cells in complex with MHC class II proteins. These complexes are recognized by CD4+ T helper cells, triggering an anti-tumor immune response and facilitating immunosurveillance. Normally, MHC class II is expressed on professional antigen-presenting cells, but certain tumors or tumor microenvironment conditions induce MHC class II on tumor or stromal cells, influencing the effectiveness of immunotherapeutic approaches. The selective presentation of TAAs by MHC class II molecules is important for the design of cancer vaccines and for the responsiveness to checkpoint inhibitor therapies. Dysregulation or lack of this antigen presentation pathway is associated with impaired anti-tumor immunity and poorer prognosis. Modulating MHC class II expression or the range of presented tumor peptides is an area of cancer therapy development, particularly for generating effective anti-tumor vaccines and improving outcomes with immune checkpoint inhibitors[1][2][3][4][6].

Other names

Tumor-associated antigen presented by MHC class IITAA presented by MHC class IIMHC class II-restricted tumor antigen

Activation of CD4+ T helper cells via recognition of TAA-MHC class II complexes, leading to adaptive anti-tumor immune responses[2][3][4][6] - Enhancement of anti-tumor immunity by inducing or restoring presentation of TAAs by tumor or tumor-associated cells